Implications of AB0 blood group in hypertensive patients with covid-19.
ABO Blood-Group System
Adult
Aged
Betacoronavirus
/ pathogenicity
Biomarkers
/ blood
Blood Coagulation
Blood Coagulation Factors
/ analysis
Blood Pressure
COVID-19
Case-Control Studies
Comorbidity
Coronavirus Infections
/ blood
Female
Host-Pathogen Interactions
Humans
Hypertension
/ blood
Inflammation Mediators
/ blood
Italy
/ epidemiology
Male
Middle Aged
Pandemics
Pneumonia, Viral
/ blood
Prospective Studies
Risk Factors
SARS-CoV-2
Coagulopathy
Covid-19
Hypertension
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
14 08 2020
14 08 2020
Historique:
received:
09
05
2020
accepted:
06
08
2020
entrez:
18
8
2020
pubmed:
18
8
2020
medline:
28
8
2020
Statut:
epublish
Résumé
Hypertension is the most frequent co-morbidity in patients with covid-19 infection, and we might speculate that a specific blood group could play a key role in the clinical outcome of hypertensive patients with covid-19. In this prospective study, we compared 0 vs. non-0 blood group in hypertensive patients with covid-19 infection. In these patients, we evaluated inflammatory and thrombotic status, cardiac injury, and death events. Patients in non-0 (n = 92) vs. 0 blood group (n = 72) had significantly different values of activated pro-thrombin time, D-dimer, and thrombotic indexes as Von Willebrand factor and Factor VIII (p < 0.05). Furthermore, patients in non-0 vs. 0 blood group had higher rate of cardiac injury (10 (13.9%) vs. 27 (29.3%)) and death, (6 (8.3%) vs. 18 (19.6%)), (p < 0.05). At the multivariate analysis, Interleukin-6 (1.118, CI 95% 1.067-1.171) and non-0 blood group (2.574, CI 95% 1.207-5.490) were independent predictors of cardiac injury in hypertensive patients with covid-19. D-dimer (1.082, CI 95% 1.027-1.140), Interleukin-6 (1.216, CI 95% 1.082-1.367) and non-0 blood group (3.706, CI 95% 1.223-11.235) were independent predictors of deaths events in hypertensive patients with covid-19. Taken together, our data indicate that non-0 covid-19 hypertensive patients have significantly higher values of pro-thrombotic indexes, as well as higher rate of cardiac injury and deaths compared to 0 patients. Moreover, AB0 blood type influences worse prognosis in hypertensive patients with covid-19 infection.
Sections du résumé
BACKGROUND
Hypertension is the most frequent co-morbidity in patients with covid-19 infection, and we might speculate that a specific blood group could play a key role in the clinical outcome of hypertensive patients with covid-19.
METHODS
In this prospective study, we compared 0 vs. non-0 blood group in hypertensive patients with covid-19 infection. In these patients, we evaluated inflammatory and thrombotic status, cardiac injury, and death events.
RESULTS
Patients in non-0 (n = 92) vs. 0 blood group (n = 72) had significantly different values of activated pro-thrombin time, D-dimer, and thrombotic indexes as Von Willebrand factor and Factor VIII (p < 0.05). Furthermore, patients in non-0 vs. 0 blood group had higher rate of cardiac injury (10 (13.9%) vs. 27 (29.3%)) and death, (6 (8.3%) vs. 18 (19.6%)), (p < 0.05). At the multivariate analysis, Interleukin-6 (1.118, CI 95% 1.067-1.171) and non-0 blood group (2.574, CI 95% 1.207-5.490) were independent predictors of cardiac injury in hypertensive patients with covid-19. D-dimer (1.082, CI 95% 1.027-1.140), Interleukin-6 (1.216, CI 95% 1.082-1.367) and non-0 blood group (3.706, CI 95% 1.223-11.235) were independent predictors of deaths events in hypertensive patients with covid-19.
CONCLUSIONS
Taken together, our data indicate that non-0 covid-19 hypertensive patients have significantly higher values of pro-thrombotic indexes, as well as higher rate of cardiac injury and deaths compared to 0 patients. Moreover, AB0 blood type influences worse prognosis in hypertensive patients with covid-19 infection.
Identifiants
pubmed: 32799852
doi: 10.1186/s12872-020-01658-z
pii: 10.1186/s12872-020-01658-z
pmc: PMC7427694
doi:
Substances chimiques
ABO Blood-Group System
0
Biomarkers
0
Blood Coagulation Factors
0
Inflammation Mediators
0
Types de publication
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
373Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK123259
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL146691
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK033823
Pays : United States
Organisme : NIDDK NIH HHS
ID : K99 DK107895
Pays : United States
Commentaires et corrections
Type : UpdateOf
Références
N Engl J Med. 2020 Oct 15;383(16):1522-1534
pubmed: 32558485
J Am Heart Assoc. 2020 Sep;9(17):e016948
pubmed: 32633594
J Clin Med. 2020 May 11;9(5):
pubmed: 32403217
Blood. 2020 Jun 4;135(23):2033-2040
pubmed: 32339221
Diabetes Care. 2020 Jul;43(7):1408-1415
pubmed: 32430456
JAMA Cardiol. 2020 Jul 1;5(7):802-810
pubmed: 32211816
J Am Coll Cardiol. 2018 May 15;71(19):e127-e248
pubmed: 29146535
JAMA. 2005 Mar 23;293(12):1450-1
pubmed: 15784866
J Thromb Haemost. 2007 Jul;5(7):1455-61
pubmed: 17425663
J Hum Hypertens. 2000 Oct-Nov;14(10-11):687-90
pubmed: 11095159
PLoS Pathog. 2020 May 21;16(5):e1008556
pubmed: 32437478
J Clin Med. 2019 May 22;8(5):
pubmed: 31121897
Int J Antimicrob Agents. 2020 May;55(5):105954
pubmed: 32234467
Nat Med. 2003 May;9(5):548-53
pubmed: 12692541
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Clin Pathol. 2020 Jun;73(6):347-349
pubmed: 31662441
Eur J Intern Med. 2020 Aug;78:101-106
pubmed: 32586646
Immunohematology. 2009;25(2):48-59
pubmed: 19927620
Diabetes Metab. 2020 Oct;46(5):403-405
pubmed: 32447102